LifeStance Health Group (NASDAQ:LFST) Now Covered by Analysts at BMO Capital Markets

BMO Capital Markets assumed coverage on shares of LifeStance Health Group (NASDAQ:LFST) in a report published on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $8.00 price target on the stock.

A number of other research analysts have also recently commented on the company. UBS Group increased their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen downgraded LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. BTIG Research upped their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of LifeStance Health Group in a report on Wednesday, October 8th. Finally, Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, LifeStance Health Group presently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

LifeStance Health Group Price Performance

LifeStance Health Group stock traded up $0.09 during midday trading on Thursday, reaching $6.40. The company’s stock had a trading volume of 1,766,853 shares, compared to its average volume of 2,226,723. The company has a current ratio of 1.58, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The stock has a market cap of $2.49 billion, a PE ratio of -213.33 and a beta of 1.15. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30. The business has a 50-day moving average price of $5.40 and a 200-day moving average price of $5.27.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $363.81 million for the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same period last year, the company posted ($0.02) EPS. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts predict that LifeStance Health Group will post -0.18 EPS for the current year.

Insiders Place Their Bets

In other news, Director Darren M. Black sold 8,407,643 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the transaction, the director directly owned 33,524,715 shares of the company’s stock, valued at $169,970,305.05. The trade was a 20.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Silversmith Partners I. Gp, Llc sold 3,592,357 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $18,213,249.99. Following the completion of the transaction, the insider directly owned 14,324,197 shares in the company, valued at approximately $72,623,678.79. This trade represents a 20.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,407,643 shares of company stock worth $103,466,750. Company insiders own 3.20% of the company’s stock.

Institutional Trading of LifeStance Health Group

Several large investors have recently made changes to their positions in the company. Creative Planning bought a new position in shares of LifeStance Health Group in the third quarter valued at $1,429,000. Lazard Asset Management LLC acquired a new stake in shares of LifeStance Health Group in the 3rd quarter worth about $269,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after acquiring an additional 1,839,465 shares during the last quarter. Integral Health Asset Management LLC bought a new position in LifeStance Health Group in the 3rd quarter valued at about $8,250,000. Finally, Marshall Wace LLP acquired a new position in LifeStance Health Group during the 3rd quarter valued at about $7,637,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.